Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

NCT01989546 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

9

Enrollment

NIH

Sponsor class

Conditions

Advanced Ovarian Cancer
Primary Peritoneal Cancer
Advanced Breast Cancer
Advanced Solid Tumors

Interventions

DRUG: BMN 673

Sponsor

National Cancer Institute (NCI)